Every protocol below requires at least a current CMP, plus any additional labs noted on its panel. Compounded medications additionally require a telehealth visit. Order labs through our Fullscript network, have us bill your insurance if you're covered, or, if you've had them done within the last 12 months, just email us your results and we'll review them. Nothing here is a claim of safety or effectiveness — it's the same plain-language briefing our providers give in the clinic.
GLP-1 receptor agonists used to support appetite regulation, glycemic response, and weight management. Where an FDA-approved brand-name option is appropriate for you, your provider will discuss that first; personalized compounding is reserved for cases where it's clinically indicated based on your individual evaluation and current pharmacy regulations.
Telehealth visit before approval, then periodic check-ins and lab retesting on a schedule your provider sets.
Tirzepatide: $199 (10mg) — or $99/mo for 2 months at 2.5mg dosing; $360 (60mg). Semaglutide: $235 (10mg). Compounded with B12 or Glycine.
An amylin-analog peptide often discussed alongside GLP-1 therapy for appetite and satiety support. It is not FDA-approved on its own and is prescribed at your provider's clinical discretion, sometimes alongside a GLP-1 protocol.
Reviewed on the same cadence as your GLP-1 protocol when co-prescribed.
Starting at $150 (10mg).
A synthetic peptide fragment widely explored in recovery-focused protocols. It is not FDA-approved for human use, and any prescription reflects your provider's individual clinical judgment.
Baseline labs reviewed prior to approval; retesting typically at 90 days or protocol renewal.
Starting at $80 (30-tablet option) — $85 (10mg injectable), $110 (20mg injectable).
An oral compound that affects norepinephrine, dopamine, and serotonin reuptake, explored for appetite suppression. It is not FDA-approved, carries stimulant-like cardiovascular effects, and is prescribed only after your provider reviews your cardiovascular history and current medications.
Blood pressure and heart rate reviewed prior to approval and at each renewal, given its stimulant-like profile.
Starting at $150 (30-tablet, 500mcg) — $220 (100-tablet, 500mcg).
A peptide fragment often discussed alongside BPC-157 for tissue-recovery protocols. Like BPC-157, it is not FDA-approved for human use and is prescribed at your provider's clinical discretion.
Reviewed alongside BPC-157 when co-prescribed; same 90-day retest cadence applies.
Starting at $70 (5mg) — $80 (10mg), $125 (20mg).
A peptide related to erythropoietin that doesn't affect red blood cell production, explored for its tissue-protective and anti-inflammatory signaling. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline CBC/CMP reviewed prior to approval; retested at renewal.
Starting at $85.
A small tripeptide fragment of alpha-MSH explored for anti-inflammatory and gut-related support. It is not FDA-approved for human use and reflects an individualized clinical decision.
Reviewed alongside other recovery peptides when co-prescribed.
Starting at $80 (5mg).
A peptide explored for its role in inhibiting myostatin, a protein that limits muscle growth. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion following review of your goals and history.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
$190 (1mg).
A combination of two growth-hormone-releasing compounds frequently used together. Neither is FDA-approved for the uses described here; prescribing reflects individualized clinical review, including your IGF-1 level.
IGF-1 is rechecked periodically to keep dosing inside a reasonable physiologic range.
2X Blend (CJC-1295 No DAC / Ipamorelin, 5mg/5mg): $85. Individual vials also available — CJC-1295 No DAC $80, CJC-1295 With DAC $155, Ipamorelin $65.
A GHRH analog with an FDA-approved indication for reducing excess visceral fat in a specific patient population. Use outside that indication is off-label and reflects your provider's individualized judgment.
IGF-1 and glucose markers rechecked periodically, since GH-axis peptides can shift blood sugar.
Starting at $85 (10mg).
A compound that acts through the central nervous system rather than the vascular system. An FDA-approved injectable form exists for a specific indication in women; compounded and other formulations are prescribed at your provider's discretion following evaluation.
Blood pressure and general health reviewed prior to approval and at renewal.
Starting at $60 (5mg) — $70 (10mg).
A peptide involved in regulating the hormone signals that drive the reproductive axis, explored for hormone and libido support. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; hormone panel rechecked as your provider indicates.
Starting at $65 (5mg) — $80 (10mg).
A naturally occurring copper-binding peptide widely explored in skin and connective-tissue support, available in injectable and topical forms. Not FDA-approved for the injectable uses described; prescribed at your provider's discretion.
Baseline labs reviewed prior to approval; retested at renewal.
Starting at $65 (50mg) — $85 (100mg).
A peptide that stimulates melanin production and is also explored for appetite and libido effects. It is not FDA-approved and carries a distinct side-effect profile your provider will review with you, including effects on existing moles and pigmentation.
Skin exam reviewed prior to approval given effects on pigmented lesions; follow-up at renewal.
Starting at $60 (10mg).
A peptide derived from a fragment of ACTH, explored for focus and cognitive support. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $80 (30mg).
A synthetic peptide explored for stress and anxiety support. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $60 (5mg) — $75 (10mg).
A peptide explored for sleep quality and stress support. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $60 (5mg) — $80 (10mg).
A neuropeptide hormone explored for mood, connection, and stress support. Not FDA-approved for the general wellness uses described here; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $60 (5mg) — $75 (10mg).
A naturally occurring thymic peptide explored for immune system support. Not FDA-approved for the general wellness uses discussed here; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $75 (10mg).
A coenzyme involved in cellular energy production, explored for recovery and general wellness support. Not FDA-approved for the uses described here; prescribed at your provider's clinical discretion. Available in biofermented and synthetic forms.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Synthetic (1000mg): $100. Biofermented (1000mg): $150.
A synthetic peptide related to a naturally occurring pineal gland compound, explored in longevity and sleep-cycle research. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $65 (10mg) — $100 (50mg).
A naturally occurring antimicrobial peptide involved in the body's immune defenses, explored for immune and tissue-support protocols. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $80 (5mg) — $100 (10mg).
A peptide encoded within mitochondrial DNA, explored for metabolic and cellular energy support. Not FDA-approved for the uses described; prescribed at your provider's clinical discretion.
Baseline metabolic labs reviewed prior to approval; standard 90-day retest cadence.
Starting at $75 (10mg).
A peptide explored in early-stage senescent-cell ("senolytic") research. This is one of the newer, less-established compounds in our library — evidence is still emerging, it is not FDA-approved, and it's prescribed only after a direct conversation with your provider about what is and isn't yet known.
Discussed in detail at your telehealth or in-person visit before approval; close follow-up given how new this compound is.
$165 (15mg).
Our combination blend pairing GHK-Cu with BPC-157 and TB-500 for patients focused on skin quality alongside general tissue recovery. Glow 50 and Glow 70 refer to concentration tiers your provider will match to your protocol.
Reviewed as a combination — each component follows its individual retest cadence.
Glow 50 (GHK-Cu 30mg / BPC-157 10mg / TB-500 10mg): $100. Glow 70 (GHK-Cu 50mg / BPC-157 10mg / TB-500 10mg): $150.
Our most-requested recovery combination, pairing BPC-157 and TB-500 for patients working through active rehab or heavy training loads.
Standard 90-day retest cadence for the combined protocol.
Starting at $75 (BPC-157 5mg / TB-500 5mg) — $110 (10mg/10mg).
If you're already working with our providers on a different protocol, request access and we'll route your labs to the right panel.
Contact Our TeamCompounded medications, including personalized GLP-1 formulations, are subject to evolving federal and state pharmacy regulations. Your provider will always tell you what's currently permissible and what your options are, including FDA-approved alternatives.
See the Full Process